Previous 10 | Next 10 |
2024-04-11 09:15:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – April 11, 2024 – USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 mill...
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23 rd Annual Needham Virtual Health...
2024-03-22 17:51:46 ET Summary G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lun...
- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA Revenue Grew 29% in the Fourth Quarter of 2023 to $13.9 Million - - Anno...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD C...
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2...
A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.8% to $4.59 on volume of 199,345,543 shares PROSHARES TRUST (SQQQ) rose 4.8% to $11.8 on volume of 167,281,450 shares S&P 500 ETF TRUST ETF (SPY) fell 1.4% to $494.08 on vo...
2024-02-13 16:06:50 ET More on G1 Therapeutics G1 Therapeutics: New Financials And Big Data Readout Alert G1 Therapeutics: Flying Low, Too Low G1 Therapeutics stock dives 36% post-market on P3 study update Seeking Alpha’s Quant Rating on G1 Therapeutic...
A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 8.2% to $4.695 on volume of 175,998,839 shares PROSHARES TRUST (SQQQ) rose 6.5% to $11.995 on volume of 143,217,194 shares Ohmyhome Limited (OMH) rose 105.6% to $2.55 on volume o...
News, Short Squeeze, Breakout and More Instantly...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 AD...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today a...